Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
Highlight
– In a randomized phase III trial of 717 patients with triple‑negative breast cancer (TNBC), adding weekly carboplatin (AUC‑2) to a sequential paclitaxel → anthracycline‑cyclophosphamide neoadjuvant program did not meet the primary end point of event‑free survival (EFS) (HR 0.80; 95% CI 0.62–1.03; P = .081).
– A secondary analysis showed improved overall survival (OS) with carboplatin (HR 0.74; 95% CI 0.57–0.97; nominal P = .029), and a strong, statistically significant interaction by menopausal status: benefit concentrated in premenopausal patients (EFS HR 0.61; OS HR 0.57), with no apparent benefit in postmenopausal patients.
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.